Huabei Pharmaceutical's Amoxicillin Sodium and Clavulanate Potassium for Injection Passed the Consistency Evaluation of Generic Drugs

On August 26, North China Pharmaceutical issued an announcement stating that it had recently received the "Notice of Approval of Supplementary Drug Application" for Amoxicillin Sodium and Clavulanate Potassium for Injection (0.
3g, 0.
6g, 1.
2g) approved by the National Medical Products Administration.
, The drug passed the consistency evaluation of the quality and efficacy of generic drugs (hereinafter referred to as "consistency evaluation")
.

Amoxicillin is a penicillin-type broad-spectrum β-lactam antibiotic.
It has strong antibacterial and bactericidal effects on most pathogenic gram-positive and gram-negative bacteria, but amoxicillin is susceptible to resistance The β-lactamase produced by bacteria is degraded; Clavulanic acid is an irreversible β-lactamase inhibitor, which can inactivate β-lactamase and reduce the degree of amoxicillin hydrolysis by β-lactamase.
To reduce the chance of drug resistance
.